FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an animal other than human for expression of human transthyretin (hereinafter – TTR) protein or chimeric TTR protein, including genetically modified endogenous Ttr locus including a human TTR sequence including both a TTR-encoding sequence and a non-encoding sequence, its cell, as well as to a method for its production. A nucleic acid molecule encoding the above-mentioned antibody or its fragment, as well as a cell and a vector containing it are also disclosed. The invention also relates to a method for the production of an antibody against Abeta or its antigen-binding fragment.
EFFECT: invention is effective for optimization of activity of a human TTR-targeting reagent in vivo, as well as for assessment of activity of the human TTR-targeting reagent in vivo.
26 cl, 20 dwg, 11 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NON-HUMAN ANIMALS CONTAINING HUMANISED ALBUMIN LOCUS | 2020 |
|
RU2815514C2 |
| ANIMALS OTHER THAN HUMANS CHARACTERIZED IN EXPANSION OF HEXANUCLEOTIDE REPEATS AT LOCUS C9orf72 | 2017 |
|
RU2760877C2 |
| CAS-EXPRESSING MOUSE EMBRYONIC STEM CELLS, AND MICE AND THEIR USE | 2018 |
|
RU2782358C2 |
| METHODS AND COMPOSITIONS FOR ASSESSMENT OF MEDIATED CRISPR/CAS DESTRUCTION OR CUTOUT AND INDUCED CRISPR/CAS RECOMBINATION WITH EXOGENEOUS DONOR NUCLEIC ACID IN VIVO | 2018 |
|
RU2782356C2 |
| METHODS AND COMPOSITIONS FOR GENOME TARGETED MODIFICATION | 2014 |
|
RU2725520C2 |
| METHODS AND COMPOSITIONS FOR DIRECTED GENOME MODIFICATION | 2020 |
|
RU2751237C1 |
| MICE CONTAINING MUTATIONS, AS A RESULT OF WHICH FIBRILLIN-1 SHORTENED AT C-TERMINUS IS EXPRESSED | 2017 |
|
RU2721125C1 |
| ANIMALS OTHER THAN A HUMAN HAVING A STRUCTURED ANGPTL8 GENE | 2017 |
|
RU2742354C2 |
| HUMANIZED T-CELL MEDIATED IMMUNE RESPONSES IN NON-HUMAN ANIMALS | 2016 |
|
RU2732628C2 |
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED ASGR1 LOCUS | 2018 |
|
RU2796949C2 |
